home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 05/13/24

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics &...
MRUS - Merus GAAP EPS of -$0.59 beats by $0.20, revenue of $7.89M misses by $0.45M

2024-05-09 12:45:05 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement FDA accepts Merus application for Zeno for lung, pancreatic cancer Gilead to invest in Merus as part of a research deal Seeking Alpha’s Quant ...

MRUS - Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDAC Based on the Companyȁ...

MRUS - FDA accepts Merus application for Zeno for lung, pancreatic cancer

2024-05-06 16:45:41 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Gilead to invest in Merus as part of a research deal Seeking Alpha’s Quant Rating on Merus Historical earnings data for Merus Financia...
MRUS - Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today an...

MRUS - Expected US Company Earnings on Thursday, May 2nd, 2024

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

MRUS - Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation ...
MRUS - Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific anti...

MRUS - (MRUS) Trading Advice

2024-04-03 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MRUS - Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M....
Previous 10 Next 10